

:: Therapeutic pipeline

VAS203

VAS203 is an allosteric NO synthase inhibitor which interacts with the BH4 binding site (cofactor tetrahydrobiopterin) of the enzyme. It is the first drug targeting both brain vasculature and parenchyma and therefore represents a completely novel and unique pharmacological approach for the treatment of traumatic brain injury. **vasopharm** completed a first-in-man study in July 2007. In June 2008 a clinical trial phase Ib (repetitive dosing) was successfully completed. The primary objective of an explorative European phase IIa multicenter study is to investigate safety and tolerability as well as pharmacodynamic effects of VAS203 in patients with CHI, in comparison to placebo. VAS203 is covered by a number international patents owned by **vasopharm** providing exclusivity until at least 2022. Patents cover both target and composition of matter.

Facts Sheet VAS203

VAS2870

VAS2870 is a NAD(P)H oxidase (NOX) modulator identified for the treatment of peripheral arterial occlusive diseases (PAOD). VAS2870 is one of several NOX modulators under evaluation at vasopharm. Compounds of this class – which are able to increase biologically available NO in progressive and chronic diseases – have potential in the treatment of the underlying causes of several cardiovascular diseases.